281 related articles for article (PubMed ID: 9723421)
1. Blocking T-cell costimulation to prevent transplant rejection.
Zheng XG; Turka LA
Transplant Proc; 1998 Aug; 30(5):2146-9. PubMed ID: 9723421
[No Abstract] [Full Text] [Related]
2. Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease.
Khoury S; Sayegh MH; Turka LA
Int Rev Immunol; 1999; 18(3):185-99. PubMed ID: 10614723
[TBL] [Abstract][Full Text] [Related]
3. Treatment of autoimmunity by inhibition of T cell costimulation.
Daikh DI; Wofsy D
Adv Exp Med Biol; 2001; 490():113-7. PubMed ID: 11505969
[No Abstract] [Full Text] [Related]
4. Transplantation and the CD28/CTLA4/B7 pathway.
Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
[No Abstract] [Full Text] [Related]
5. Simultaneous blockade of B7-CD28 and CD40-CD40L costimulation eliminates the direct xenorestricted human anti-porcine T-cell response.
Popma SH; Krasinskas AM; Kreisel D; Szeto W; McLean AD; Moore JS; Rosengard BR
Transplant Proc; 2001; 33(1-2):767-9. PubMed ID: 11267061
[No Abstract] [Full Text] [Related]
6. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses.
Lee RS; Yamada K; Womer KL; Pillsbury EP; Allison KS; Marolewski AE; Geng D; Thall AD; Arn JS; Sachs DH; Sayegh MH; Madsen JC
J Immunol; 2000 Mar; 164(6):3434-44. PubMed ID: 10706740
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs survival in small bowel transplantation.
Kurlberg G; Haglind E; Schön K; Törnqvist H; Lycke N
Scand J Immunol; 2000 Mar; 51(3):224-30. PubMed ID: 10736090
[TBL] [Abstract][Full Text] [Related]
8. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts.
Williams MA; Trambley J; Ha J; Adams AB; Durham MM; Rees P; Cowan SR; Pearson TC; Larsen CP
J Immunol; 2000 Dec; 165(12):6849-57. PubMed ID: 11120808
[TBL] [Abstract][Full Text] [Related]
9. CD28/CTLA-4 and CD80/CD86 costimulatory molecules are mainly involved in acceptance or rejection of human liver transplant.
Minguela A; Marín L; Torío A; Muro M; García-Alonso AM; Moya-Quiles MR; Sánchez-Bueno F; Parrilla P; Alvarez-López MR
Hum Immunol; 2000 Jul; 61(7):658-69. PubMed ID: 10880736
[TBL] [Abstract][Full Text] [Related]
10. The ups and downs of T cell costimulation.
Jenkins MK
Immunity; 1994 Sep; 1(6):443-6. PubMed ID: 7534615
[No Abstract] [Full Text] [Related]
11. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts.
Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S
Transplant Proc; 1999; 31(1-2):1244. PubMed ID: 10083555
[No Abstract] [Full Text] [Related]
12. Blockade of costimulation prevents infection-induced immunopathology in interleukin-10-deficient mice.
Villegas EN; Wille U; Craig L; Linsley PS; Rennick DM; Peach R; Hunter CA
Infect Immun; 2000 May; 68(5):2837-44. PubMed ID: 10768980
[TBL] [Abstract][Full Text] [Related]
13. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients.
Pistillo MP; Tazzari PL; Bonifazi F; Bandini G; Kato T; Matsui T; Nishioka K; Conte R; Ferrara GB
Transplantation; 2002 Apr; 73(8):1295-302. PubMed ID: 11981425
[TBL] [Abstract][Full Text] [Related]
14. CD28-specific antibody prevents graft-versus-host disease in mice.
Yu XZ; Bidwell SJ; Martin PJ; Anasetti C
J Immunol; 2000 May; 164(9):4564-8. PubMed ID: 10779758
[TBL] [Abstract][Full Text] [Related]
15. New protein steals the show as 'costimulator' of T cells.
Cohen J
Science; 1993 Nov; 262(5135):844-5. PubMed ID: 7694360
[No Abstract] [Full Text] [Related]
16. The complexities of T-cell co-stimulation: CD28 and beyond.
Sperling AI; Bluestone JA
Immunol Rev; 1996 Oct; 153():155-82. PubMed ID: 9010723
[No Abstract] [Full Text] [Related]
17. The Yin and Yang of T cell costimulation.
Allison JP; Krummel MF
Science; 1995 Nov; 270(5238):932-3. PubMed ID: 7481795
[No Abstract] [Full Text] [Related]
18. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
[No Abstract] [Full Text] [Related]
19. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
20. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T cells.
Eck SC; Turka LA
Cancer Immunol Immunother; 1999 Sep; 48(6):336-41. PubMed ID: 10473809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
